22 Nov 2022 argenx announces U.S. FDA acceptance of biologics license application for subcutaneous efgartigimod in generalized myasthenia gravis with priority review Member news
21 Nov 2022 Oxurion: Interim analysis for KALAHARI trial planned by year-end 2022 with full top-line data expected in second half of 2023 Member news
17 Nov 2022 BGV co-leads €10 million seed investment in neuroscience company FundaMental Pharma Member news
15 Nov 2022 Rejuvenate Biomed’s newly appointed Clinical Advisory Board endorses Clinical Phase 2b strategy in sarcopenia Member news
15 Nov 2022 Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKON Member news
14 Nov 2022 UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients Member news
11 Nov 2022 Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors Member news
08 Nov 2022 BIO INX and Nanoscribe expand their partnership with the launch of HYDROBIO INX© N400, a new biocompatible high resolution bioink enabling live cell encapsulation Member news
08 Nov 2022 New Idylla™ EGFR study shows reduction of time-to-treatment by 48% for lung cancer patients Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
